![Dose escalation design for the Part 1 of the trial. Single patients... | Download Scientific Diagram Dose escalation design for the Part 1 of the trial. Single patients... | Download Scientific Diagram](https://www.researchgate.net/publication/358312105/figure/fig1/AS:1155450561146881@1652492289655/Dose-escalation-design-for-the-Part-1-of-the-trial-Single-patients-were-enrolled-in-Dose.png)
Dose escalation design for the Part 1 of the trial. Single patients... | Download Scientific Diagram
![Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet](https://www.thelancet.com/cms/asset/1b910723-0066-4d56-b1fc-a26b052120ea/gr1.jpg)
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet
![Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial | JACC: Heart Failure Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial | JACC: Heart Failure](https://www.jacc.org/cms/asset/499a637d-3858-4b3e-931b-cdd4840e8ee6/fx1.jpg)
Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial | JACC: Heart Failure
![Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial | Journal of the American College of Cardiology Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/388fa047-236e-4baf-af5a-650a7c6451d5/gr4.jpg)
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial | Journal of the American College of Cardiology
![Preliminary dose trial therapy. Presentation of the effect in reduction... | Download Scientific Diagram Preliminary dose trial therapy. Presentation of the effect in reduction... | Download Scientific Diagram](https://www.researchgate.net/publication/281299075/figure/fig47/AS:614326272540684@1523478205698/Preliminary-dose-trial-therapy-Presentation-of-the-effect-in-reduction-of-tumor-growth.png)
Preliminary dose trial therapy. Presentation of the effect in reduction... | Download Scientific Diagram
![First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers: Molecular Therapy - Nucleic Acids First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/asset/16817793-978c-4627-9960-a268f7a3796c/fx1.jpg)
First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers: Molecular Therapy - Nucleic Acids
![Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01632-2/MediaObjects/41416_2021_1632_Fig1_HTML.png)
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer
![Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial - The Lancet Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial - The Lancet](https://www.thelancet.com/cms/attachment/2001002884/2003737585/gr1.gif)
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial - The Lancet
![Vaccines | Free Full-Text | The Correlated Beta Dose Optimisation Approach: Optimal Vaccine Dosing Using Mathematical Modelling and Adaptive Trial Design Vaccines | Free Full-Text | The Correlated Beta Dose Optimisation Approach: Optimal Vaccine Dosing Using Mathematical Modelling and Adaptive Trial Design](https://www.mdpi.com/vaccines/vaccines-10-01838/article_deploy/html/images/vaccines-10-01838-g001.png)
Vaccines | Free Full-Text | The Correlated Beta Dose Optimisation Approach: Optimal Vaccine Dosing Using Mathematical Modelling and Adaptive Trial Design
![Trial design and dosing schema. (a) The trial replicates patients' last... | Download Scientific Diagram Trial design and dosing schema. (a) The trial replicates patients' last... | Download Scientific Diagram](https://www.researchgate.net/publication/259766248/figure/fig1/AS:267507961430024@1440790276290/Trial-design-and-dosing-schema-a-The-trial-replicates-patients-last.png)
Trial design and dosing schema. (a) The trial replicates patients' last... | Download Scientific Diagram
![Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine](https://www.thelancet.com/cms/asset/35f46ecb-de52-4c1e-b619-9067dc01b530/gr1.jpg)
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine
![Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial - eClinicalMedicine Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial - eClinicalMedicine](https://www.thelancet.com/cms/attachment/596fab91-d995-4289-b14d-237f412f9483/gr1_lrg.jpg)
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial - eClinicalMedicine
![A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers | BMC Pulmonary A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers | BMC Pulmonary](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12890-018-0763-9/MediaObjects/12890_2018_763_Fig1_HTML.png)
A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers | BMC Pulmonary
![Antioxidants | Free Full-Text | Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial Antioxidants | Free Full-Text | Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial](https://www.mdpi.com/antioxidants/antioxidants-10-01270/article_deploy/html/images/antioxidants-10-01270-g001-550.jpg)
Antioxidants | Free Full-Text | Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial
![Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial - ScienceDirect Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121014750-grabsf1.jpg)